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Abstract
Background: The risk associated with methicillin-resistant Staphylococcus aureus (MRSA) has been
decreasing for several years in intensive care departments, but is now increasing in rehabilitation
and chronic-care-facilities (R-CCF). The aim of this study was to use published data and our own
experience to discuss the roles of screening for MRSA carriers, the type of isolation to be
implemented and the efficiency of chemical decolonization.
Discussion: Screening identifies over 90% of patients colonised with MRSA upon admission to R-
CCF versus only 50% for intensive care units. Only totally dependent patients acquire MRSA. Thus,
strict geographical isolation, as opposed to "social reinsertion", is clearly of no value. However, this
should not lead to the abandoning of isolation, which remains essential during the administration
of care. The use of chemicals to decolonize the nose and healthy skin appeared to be of some value
and the application of this procedure could make technical isolation unnecessary in a non-negligible
proportion of cases.
Summary:  Given the increase in morbidity associa t e d  w i t h  M R S A  o b s e r v e d  i n  n u m e r o u s
hospitals, the emergence of a community-acquired disease associated with these strains and the
evolution of glycopeptide-resistant strains, the voluntary application of a strategy combining
screening, technical isolation and chemical decolonization in R-CCF appears to be an urgent matter
of priority.
Background
Methicillin-resistant Staphylococcus aureus (MRSA) strains
were first identified in the early 1960's [1]. They now have
a worldwide distribution [2] and have evolved resistance
to multiple antibiotics. The recent description of clinical
strains highly resistant to glycopeptides following the
acquisition of the vanA gene has increased fears that it will
soon be impossible to treat patients infected with these
epidemic strains [3]. The prevalence of MRSA in France is
among the highest in the European Union [4,5], and a
recent publication by a regional surveillance network
showed that this prevalence continued to increase
between 1996 and 2000 [6].
Since the first half of the 1990's, most intensive care units,
in which the risks associated with MRSA are very high,
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have implemented prevention measures. These measures
have proved to be effective, as shown by stabilisation of
the number of MRSA infections in hospitals in which the
risk was increasing or by an even greater reduction in the
number of MRSA infections in these units than in other
types of unit in which the risk was tending to decrease [6-
8]. Conversely, the situation has deteriorated considera-
bly in R-CCF [6,9], despite the widespread diffusion of
national recommendations by the Comité Technique
National des Infections Nosocomials (CTIN or National
Technical Committee for Nosocomial Infections) [10].
These recommendations of the French CTIN, presented in
table 1, were strongly recommended in acute care facilities
but should be also applied in R-CCF. However, concerns
were encountered when implementing these measures in
this kind of departments because the mean length of hos-
pitalisation is much longer, the ratio of patients to medi-
cal staff ratio is higher and the patients need to take part
in physical and social activities, which are considered to
be incompatible with isolation precautions [10-13].
The recommendations published by the CTIN target, as a
matter of priority, MRSA and Enterobacteria producing
extended-spectrum  β-lactamases, as these bacteria are
highly pathogenic and commensal, favouring their clonal
spread within hospitals and raising fears for their spread
in the community. The CTIN suggests that patients colo-
nised/infected with MRSA should be identified, that these
patients should be placed in isolation and that comple-
mentary measures should be implemented, including
screening for carriers upon admission and during hospi-
talisation and treating human reservoirs (see table 1). Sev-
eral questions concerning the application of these
measures in R-CCF remain unanswered, notably due to
difficulties evaluating the effect of any given measure
within a wider strategy. Given the lack of evidence to dem-
onstrate the efficacy of some measures and a lack of
means, the concerned establishments have implemented
the recommendations of the CTIN only half-heartedly [6].
For several years, the Hygiene Department of Besançon
University Hospital has placed all its means (computer
facilities and biological platform) and competences at the
disposal of a 120-bed chronic-care-centre (Tilleroyes
Health Care Centre), with a view to controlling MRSA
infections. As most of chronic-care-centers in France, the
Tilleroyes Centre admitted more than 90% of elderly
patients coming from acute care facilities. These patients
are hospitalised approximately during 30 days and
received mainly nursing cares and incidentally invasive
medical cares. The aim of this article was to use the expe-
rience acquired and published data as a basis for consid-
ering the efficacy and feasibility of some of these
measures, particularly those frequently contested by
health professionals involved in the fight against nosoco-
mial infections in R-CCF: screening, isolation and chemi-
cal decolonization.
Discussion
The occurrence of MRSA in rehabilitation and long-term-
care-facilities
In the study carried out by the Microbiology Surveillance
Network of Northern France [6], the incidence of MRSA
colonisation/infection in chronic-care-facilities was 0.69
per 1000 days of hospitalisation. This incidence increased
significantly between 1996 and 2000, such that it was
similar to the mean observed in all types of ward and in
all hospitals considered together (0.84 per 1000 days).
The frequency of methicillin resistance was considerably
higher than that in other types of unit (61% versus 14.4 to
42.5%). In the Franche-Comté region of France, the inci-
dence of MRSA in rehabilitation units was 0.55 per 1000
days in 2002, which is identical to the overall incidence in
all types of ward, and the frequency of resistance was prac-
tically identical to that reported in northern France
Table 1: Recommendations of French CTIN for the control of MRSA
Early identification of patients colonized and/or infected with MRSA
Information of the status of the previously known MRSA positive patients at the time of hospital-to-hospital or ward-to-ward transfer
Detection of MRSA colonization and/or infection based on clinical samples
Detection of MRSA carriage based on screening samples (without precision on which sites should be cultured) at admission and during hospitalisation in high 
risk MRSA acute care facilities or in all facilities in case of outbreaks
Barrier isolation of MRSA positive patients
Technical isolation including
Compliance to hand disinfection,
Use of gloves and gowns for all contact with patients or their environment,
Use of dedicated medical equipments
Geographical isolation (individual rooms) or cohorting "which considerably facilitates the application of technical isolation"*
Decolonization with mupirocin associated with antiseptic daily body cleansing*
The procedures mentionned in italic are proposed by the CTIN as complementary measures and are implemented according epidemiological 
situation of the hospital and/or the wardBMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/5
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(62%). Despite these figures, the direct effect of MRSA
infections in R-CCF appears to be limited, given the sever-
ity of the associated morbidity. In fact, two severe infec-
tions (one case of bacteraemia and one case of deep
infection) were observed in the 26 colonised/infected
patients (7.7%), whereas 20.7% of the colonised/infected
patients in acute-care units had severe infections (35
infections, including 16 cases of bacteraemia, 11 deep
infections and eight lung infections diagnosed from sam-
ples taken during invasive interventions, in a total of 169
colonised/infected patients). However, given that patients
are continually transferred between R-CCF and acute-care
facilities, it is reasonable to consider these units together
with all other care units and to measure the effect of MRSA
on a regional health care network rather than on the scale
of a given ward or hospital. If this approach is used, the
rare figures available show the amplification effect of R-
CCF on MRSA propagation (11.6% of patients were carri-
ers upon admission versus 18.7% upon discharge) [14].
Several studies carried out in intensive care units have
shown that the duration of hospitalisation is a risk factor
for MRSA colonisation/infection [15,16]. It therefore
seems logical that hospitalisation in R-CCF may amplify
the spread of MRSA. Furthermore, the high frequency of
"openly" colonisations/infections like urinary infections
or colonised wounds, favours the spread of strains both
on the hands of staff and via the inert environment [17-
19].
Role of screening
Cookson reported that the transfer of patients between
hospitals is the second most important way of increasing
the risk of MRSA in a given hospital and indicated that
interactions between acute-care hospitals and R-CCF may
lead to the spread of MRSA in the community [20,21]. The
identification of all reservoirs (colonised/infected patients
and simple carriers) within wards is considered to be a
major component of all control programmes [22-24] and
the isolation strategies recommended to prevent cross-
transmission may be hindered if carriers are not identified
upon admission. The collection of samples for screening,
the usefulness and cost/benefit ratio of which remain
open to debate [11,22], is indispensable both for the iden-
tification of colonised/infected patients and carriers and
for the prevention of secondary infections in carriers [25].
In intensive care units, the efficacy and favourable cost/
benefit ratio of setting up a voluntary strategy for the pre-
vention of MRSA infections that involves screening have
been demonstrated [25-27]. However, the efficacy of
screening has also been demonstrated, in the absence of
cost/benefit evaluation, in R-CCF [14]. The results with
respect to the criteria for efficacy in the two types of unit
(intensive care units and R-CCF) are summarised in Table
2. This table shows that for each judgement criterion for
which it was possible to compare the two types of unit, a
strategy including screening was even more pertinent for
R-CCF than for intensive care units. Establishments with
one or several intensive care units have in-house microbi-
ology-hygiene laboratories and can screen patients at a
reasonable cost. This is not the case for R-CCF, who must
avail themselves of the services of an external laboratory,
which is likely to be very expensive. These economic rea-
sons dissuade hygiene professionals from implementing
screening policies even though this expenditure has bene-
fits in terms of the reduction in the number of MRSA
infections and the costs associated with such infections in
acute-care units.
Role of isolation
The recommendations published by the CTIN are based
on both technical isolation and geographical isolation,
which "considerably facilitates the application of
technical isolation measures" [10]. Citing this principle
and the need to "resocialise" the patient, professionals
working in R-CCF often state that isolation is "not possi-
ble" in their structure and suggest a policy based only on
standard precautions. The main arguments against
isolation are the need to allow patients free access to the
Table 2: Efficiency of screening according to the type of department
R-LTCFa N(%) Intensive careb N (%)
Patients positive on admission 60 (11.6) 150 (4.1)
Screened 55 (91.6) 76 (50.7)
Identified by CSc 5 (8.4) 74 (49.3)
Knownd 18 (30) 30 (20)
Time to screening /CS + NDe 6.7 +/- 7.3 days
Positive on discharge 62 (18.7) NDe
Known 26 (41.9) NDe
Screened 36 (58.1) NDe
aTalon et al. (14) for R-LTCF (Rehabilitation and long-Term-care Facilities) bGirou et al. (25) for intensive care units; cCS, clinical sample, dpatients 
previously known to be carriers, colonised or infected; eND, not doneBMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/5
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dining room and the common room, where they meet
other patients, which may result in the direct transmission
of MRSA. In the case of an epidemic, it is often possible to
identify reservoirs, but it is always more difficult to iden-
tify modes of transmission with certainty. Are MRSA
directly transmitted from patient to patient or on the
hands of the healthcare staff? It is impossible to determine
accurately the part played by these two modes of transmis-
sion. However, we know that the replacement of a dress-
ing covering a colonised wound poses a high risk of
contamination for the immediate environment, including
the hands of staff, because it creates an aerosol heavily
loaded with bacteria [28]. It is obvious that simple contact
between two patients is not associated with the same risk
of transmission: the contact is less intense, the contact is
with skin, which is much less densely colonised, and there
is an absence of aerosols heavily loaded with bacteria.
Another more direct argument comes from the non-pub-
lished risk of acquiring MRSA stratified according to Katz's
index, an index of autonomy [29]. According to this
index, patients are classified into seven categories: from A
for a totally autonomous patient to G for patients totally
dependent on others for assistance with washing, dress-
ing, using the toilet, moving around, continence and feed-
ing (the intermediate categories are based on scores for
each function, with three choices for each function: no
help required, moderate help required, total help
required). The study was carried out in a 120-bed chronic-
care centre. Each patient was screened upon admission,
once per week during their stay and upon discharge. A
patient was considered to have acquired MRSA if a MRSA
was isolated from a sample taken for epidemiological or
diagnostic purposes from a patient who tested negative
upon admission. The results (Table 3) show that the glo-
bal incidence of MRSA acquisition was 7% for classes F
and G combined and 0% for classes A to E. All of this indi-
rect evidence suggests that carriage on the hands of hospi-
tal staff plays a predominant role in cross-transmission.
Thus, technical isolation rules should be respected when
carrrying out treatments, the efficacy of such isolation
being unaffected by the mobility of patients and their
"resocialisation."
Role of chemical decolonization
The CTIN suggests that human reservoirs identified by
screening should be treated "with the aim of eradicating
carriage". However, it recommends that care be taken to
prevent the emergence of resistance to the topical antibi-
otics used for this indication [10]. The treatment of nasal
MRSA carriage is recommended if the nose is the only site
colonised or if the other colonised sites are accessible to
treatment; an antiseptic wash should also be used in such
cases [10]. The recommendations also include those of
the Consensus Conference on the Control of multi-drug
resistant bacteria in Intensive Care Units [30]. The recom-
mended associated use of an antiseptic wash is justified by
the work by Moss and co-workers and by White, Reagan
and co-workers [31-33]. These authors showed that: 1)
Table 3: Incidence of acquisition of methicillin-resistant Staphylococcus aureus stratified according to Katz's index in a chronic-care 
centre.
ABCDEFG
Number of patients admitted 14 13 4 10 7 11 75
Number of acquisitionsa 0000015
I n c i d e n c e  o f  a c q u i s i t i o n  ( % ) 00000 9 . 1 6 . 7
ain patients who were not carriers (screening samples) or who were not colonised/infected (clinical samples) on admission
Table 4: Distribution of sites colonised by MRSA
Colonised on admission N (%) Acquireda N (%)
Nose 24 (9.6) 25 (10.0)
Wounds 8 (3.2) 12 (4.8)
Stools 0 (0) 1 (0.4)
Arm pits 8 (3.2) 12 (4.8)
Folds under breasts 1 (0.4) 0 (0)
Inguinal folds 1 (0.4) 2 (0.8)
Total patients 32b (12.8) 47b (18.8)
aacquired MRSA whilst in hospital, bin total, 9 and 4 patients were positive at several sites on admission and during hospitalisation, respectivelyBMC Geriatrics 2003, 3 http://www.biomedcentral.com/1471-2318/3/5
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skin colonisation is more frequent in patients carrying S.
aureus in the nose, 2) the frequency of skin colonisation
is proportional to the density of nasal colonisation and
finally 3) nasal decolonization without skin decoloniza-
tion led to a reduction of the density of skin colonisation.
Probably due to the description of strains with low and
high levels of resistance to mupirocin, which is used for
nasal decolonization [34-36], the limitation of nasal
decolonization to localised epidemics is recommended.
This implies that isolation measures should be applied to
carriers throughout the entire period of hospitalisation.
This extra work load is clearly even greater in R-CCF than
in acute-care facilities, as the mean duration of stay is 30
days in such units. This is often incompatible with the
"availability" of healthcare staff. Furthermore, the antisep-
tic solutions used to clean the skin of patients, most of
whom are elderly, are often considered to cause irritations
or allergies on sensitive skin of patients already damaged
due to prolonged bed rest. Given the "half-hearted" appli-
cation of recommendations and the reluctance associated
with theoretical arguments, no published studies have
evaluated the role of chemical decolonization in the con-
trol of MRSA in R-CCF. In our collaboration with the
chronic-care centre, independently of screening upon
admission and during hospitalisation for carriage in the
nose, wounds (including the drains and openings of the
gastric tract), healthy skin (armpits, inguinal folds and
folds beneath the breasts) and rectum (rectal swabs), it
was decided to use mupirocin twice a day during five days
to decolonize the noses of carriers (according to the rec-
ommendation of the manufacter, limited to one treat-
ment per patient) and to daily use antiseptic solution
during nasal decolonisation (Biseptine™ which contain
chlorhexidine) to decolonize the skin. During the six-
month monitoring period in one of the two departments
(60 beds), for the screening samples only, 79 of the 250
patients admitted (31.6%) were found to be colonised at
one or several sites. Table 4 summarises the sites of colo-
nisation on admission and of colonisation acquired dur-
ing hospitalisation. Nasal decolonization was successful
in 32 (18 patients colonised on admission and 14 patients
colonised in hospital) of the 49 patients who tested posi-
tive and failed in 11 cases. For 9 of these 11 failures,
another site was also colonised, this site being a wound in
8 cases. Decolonization could not be assessed in six cases,
because these cases died before discharge. Fifteen of the
21 patients (71.4%) with colonised healthy skin (armpits
+/- folds under breasts +/- inguinal folds) were success-
fully decontaminated. Four failures were observed, three
of which concerned patients colonised at another site (3
wounds). Decolonization could not be assessed in two
cases. Furthermore, recolonisation was observed in four
patients (included in the acquired cases): all four showed
nasal contamination and one of the four also had colo-
nised healthy skin. In total, decolonization was effective
at all sites of carriage in 40 patients (50.6% of the positive
patients), 19 of whom were colonised on admission and
21 of whom were colonised during their stay hospital.
This made it possible to stop technical isolation measures.
In no case was it necessary to stop Biseptine™ washes due
to intolerance or allergy. Furthermore, at Besançon Uni-
versity Hospital, the large-scale use of mupirocin for long
periods has not led to the appearance of resistance to this
topical agent [7]. The mean time to acquisition was 11
days and the mean duration of decolonization was 9 days
(decolonization: 5 days, controls carried out on 7th days
and results obtained on 9th day). The discontinuation of
isolation after effective decolonization made it possible to
reduce the number of days of isolation to about one third
(609 days compared to a theoretical total of 1853 days).
Nasal decolonization appeared to be efficient in most
cases, unless wounds were colonised. Is it necessary to dis-
infect wounds systematically? The answer to this question
is unclear: the delay in healing associated with systematic
disinfection and the very low level of efficacy observed do
not favour this practice [19]. Once again, Biseptine™,
which may carry a lower risk of delayed healing, should be
tested, using various protocols to assess its efficacy.
Summary
R-CCF are at the centre of epidemics of MRSA colonisa-
tion, even if the consequences of these epidemics in terms
of morbidity remain limited to them. The application of
an effective prevention strategy to these departments and
hospitals should considerably reduce the morbidity
linked to MRSA in acute-care units. An effective strategy
must be based on the identification of all reservoirs; it is
therefore necessary to screen all patients systematically on
admission to and discharge from these units and estab-
lishments. With this in mind, acute-care units should
make their technical facilities available to these units. The
isolation of patients identified as carriers, or colonised
and/or infected individuals does not require the geo-
graphical isolation of these patients because the most
common route of spread from patient to patient is via the
hands of staff during care. Technical isolation creates extra
work, which is not always compatible with the nursing
time available. However, this extra work load can be lim-
ited by chemical decolonization, the efficacy of which is
far from negligible. Given the increase in morbidity asso-
ciated with MRSA observed in numerous hospitals, the
emergence of a community-based disease linked to these
strains and the emergence of glycopeptide-resistant
strains, the application of a voluntary strategy including
screening, isolation and decolonization in R-CCF appears
to be an urgent matter of priority.
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